Turku, Finland -- (SBWIRE) -- 04/27/2017 -- Medicortex Finland Oy (http://www.medicortex.fi), a biotechnology company developing a diagnostic kit for brain injury detection based on a medical breakthrough biomarker, recently completed analyzing the results from the first clinical trial. Medicortex is working towards the validation of a Traumatic Brain Injury (TBI) biomarker and incorporating it into a quick and reliable diagnostic kit that can be easily used by the first responders and healthcare professionals, and by people with no medical profession.
The trial consisted of patients that were hospitalized due to a head injury. Medicortex collected body fluid samples of 12 patients who had sustained a head injury, and analyzed the presence of the novel biomarker between the patients and healthy control subjects.
"The biodegradation product we are targeting has never been used for TBI indication. The fact that we can readily find it in easily accessible body fluids such as urine and saliva enables us to develop a user-friendly diagnostic kit for TBI detection", says Dr. Adrian Harel, Chief Executive Officer of Medicortex Finland. "Collecting and testing human samples in a clinical trial is a significant accomplishment for us, and represents a meaningful step forward in the development of a fast and inexpensive diagnostic kit for head injuries," added Dr. Harel. "Brain injuries are devastating, leading to mortality if not diagnosed. The opportunity to develop the first portable non-invasive kit to detect head injuries and concussion is so desperately needed."
Dr. Marten Kvist, Medical Director of Medicortex, says "We are excited of the clinical results which confirm the diagnostic potential of the unique biomarker, it will be further developed into a diagnostic aid for first responders and paramedics, it will help prioritize evacuation and reframe from administration of contraindicated medications."
The clinical trial was supported and funded in part by Tekes (the Finnish Funding Agency for Innovation). Medicortex is currently raising money for the next step clinical development of the brain injury test. The planned multicenter clinical study including up to 160 study subjects will prove the validity of the new biomarker test for TBI diagnostics.
The general public can help contribute in the development of MediCortex's diagnostic kit via a crowdfunding campaign at http://www.invesdor.com/medicortex Medicortex is issuing shares with the goal of raising capital to match funds the firm has already applied via Tekes.
About Medicortex
Medicortex Finland Oy (http://www.medicortex.fi) is a biotechnology company dedicated to improving the diagnostics and treatment of Traumatic Brain Injury (TBI). Its current focus is to develop biomarker diagnostics that evaluate the extent and severity of TBI. Once the company completes this test its next goal will be to develop an innovative drug to halt the progression of brain injury.
Forward-Looking Statements
This press release contains statements that are "forward-looking statements" that are based upon management's current expectations and assumptions and are subject to several risks, uncertainties and other factors that could cause actual results and events to differ materially and adversely from those indicated herein.
Dr. Adrian Harel - CEO
Medicortex Finland Oy
PharmaCity
Itainen Pitkakatu 4 B, FI-20520 Turku, Finland
Tel. +358 (0) 400 488 817
Fax. +358 (0) 2 251 0100
adrian.harel@medicortex.fi
http://www.medicortex.fi